What if the mosquito net
wasn’t completely closed?

What if the mosquito net
wasn’t completely closed?

Japanese Encephalitis (JE) is a potentially severe disease – but can be preventable2,3

A traveller to any of 24 countries in Asia can be infected with Japanese Encephalitis (JE) virus. In rare cases, JE viral infection can result in encephalitis.4,5

Learn more about helping to protect travellers from Japanese Encephalitis

Help Reduce Risk for Your Patients by Knowing the Facts

CLICK TO EXPAND

KEY FACTS ABOUT JAPANESE ENCEPHALITIS

Japanese Encephalitis is not just in Japan


The Japanese Encephalitis virus is endemic to 24 countries across Asia and Southeast Asia, as well as parts of the western Pacific.
4

JE occurs across Asia

Over 70,000 symptomatic cases of JE are estimated to occur each year in Asia.4
It is not possible to predict who will develop the disease – the majority of infections in humans are asymptomatic; clinical disease develops in one in every 50 to 1,000 individuals infected.1

JE is the most common vaccine-
preventable encephalitis in Asia


JE is the leading cause of viral-induced neurologic sequelae.4,6

Up to 30% who develop JE die, and up
to 50% of JE survivors suffer long-term
sequelae
3,5*

*Neurologic, cognitive, and psychiatric sequelae4,6

There is no specific
treatment for JE

The only protection against JE is prevention6,7†

† IXIARO® is not indicated to prevent consequences of JE

CLICK TO EXPAND

KEY FACTS ABOUT JAPANESE ENCEPHALITIS

Japanese Encephalitis is not just in Japan


The Japanese Encephalitis virus is endemic to 24 countries across Asia and Southeast Asia, as well as parts of the western Pacific.
4

JE occurs across Asia

Over 70,000 symptomatic cases of JE are estimated to occur each year in Asia4
It is not possible to predict who will develop the disease – the majority of infections in humans are asymptomatic; clinical disease develops in one in every 50 to 1,000 individuals infected.1

JE is the most common vaccine
-preventable encephalitis in Asia


JE is the leading cause of viral-induced neurologic sequelae.4,6

Up to 30% who develop JE die, and up
to 50% of JE survivors suffer long-term
sequelae
3,5*

*Neurologic, cognitive, and psychiatric sequelae4,6

There is no specific
treatment for JE

The only protection against JE is prevention6,7†

† IXIARO® is not indicate to prevent consequences of JE

One vaccine can help
protect them

Consider IXIARO® for your patients aged
≥ 2 months for the prevention of JE
1

What can you do to help protect
patients against JE?

Learn more about risk reduction strategies
and vaccination for travellers at risk

What is IXIARO?®

Help prevent JE

One vaccine can help
protect them

Consider IXIARO® for your patients aged
≥ 2 months for the prevention of JE
1

What is Ixiaro?®

What can you do to help protect
patients against JE?

Learn more about risk reduction strategies
and vaccination for travellers at risk

Help prevent JE

IXIARO® is indicated for active immunization against Japanese Encephalitis for persons 2 months of age and older.

IXIARO® should be considered for use in individuals at risk of exposure through travel or in the course of their occupation. As with any other vaccine, vaccination with IXIARO® may not result in protection in all cases. IXIARO® will not protect against encephalitis caused by other micro-organisms.

Check the Safety Information section for additional information discussing

  • Contraindications: Hypersensitivity to this vaccine or to any ingredient in the formulation or component of the container; do not give the second dose to individuals who show hypersensitivity reactions after the first dose; postpone vaccination with IXIARO® in persons with acute severe febrile conditions
  • Most serious warnings and precautions regarding treating rare cases of anaphylactic reactions following the administration of the vaccine; administration of IXIARO® and bleeding disorders
  • Other relevant warnings and precautions regarding pregnant and nursing women, geriatrics (≥65 years of age) and immunosuppressed individuals
  • Conditions of clinical use, adverse reactions, drug interactions and dosing instructions

Please see IXIARO® Product Monograph for complete prescribing information.

VALNEVA Canada Inc.
600-3535, Saint-Charles Blvd.
Kirkland (Montreal), Quebec
H9H 5B9

© 2019 VALNEVA Canada Inc.
All trademarks used under license.